Zhanhong Xie Yingying Gu Xinqing Lin Ming Ouyang Yinyin Qin Jiexia Zhang Junjun Liu Suiyi Mai Chengzhi Zhou
10.1080/15384047.2019.1617561
Cancer Biol Ther
2019;20(9):1172-1175.
mutation etoposide and cisplatin non-small-cell lung cancer resistance mechanism small-cell lung cancer transformation
CC BY-NC-ND
https://pubmed.ncbi.nlm.nih.gov/31161851/
Antineoplastic Combined Chemotherapy Protocols / therapeutic use Lung Neoplasms / drug therapy Lung Neoplasms / pathology Small Cell Lung Carcinoma / drug therapy Small Cell Lung Carcinoma / pathology
Antineoplastic Combined Chemotherapy Protocols / therapeutic use Lung Neoplasms / drug therapy Lung Neoplasms / pathology Small Cell Lung Carcinoma / drug therapy Small Cell Lung Carcinoma / pathology Case Reports Antineoplastic Combined Chemotherapy Protocols / adverse effects Biomarkers, Tumor Cell Transformation, Neoplastic / genetics Cisplatin / administration & dosage Drug Resistance, Neoplasm Etoposide / administration & dosage Humans Lung Neoplasms / diagnostic imaging Lung Neoplasms / genetics Male Middle Aged Positron Emission Tomography Computed Tomography Small Cell Lung Carcinoma / diagnostic imaging Small Cell Lung Carcinoma / genetics Treatment Outcome Biomarkers, Tumor Etoposide Cisplatin
PMC6741564
31161851
Unexpected favorable outcome to etoposide and cisplatin in a small cell lung cancer transformed patient: a case report
2019